JP5559056B2 - ガンの診断、予測、および予後試験 - Google Patents

ガンの診断、予測、および予後試験 Download PDF

Info

Publication number
JP5559056B2
JP5559056B2 JP2010529444A JP2010529444A JP5559056B2 JP 5559056 B2 JP5559056 B2 JP 5559056B2 JP 2010529444 A JP2010529444 A JP 2010529444A JP 2010529444 A JP2010529444 A JP 2010529444A JP 5559056 B2 JP5559056 B2 JP 5559056B2
Authority
JP
Japan
Prior art keywords
biomarker
cancer
level
aurora
cell cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010529444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011501809A (ja
Inventor
ストーバー，カイ
ハイデン ウィリアムズ，ガレス
Original Assignee
ケンブリッジ キャンサー ダイアグノスティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケンブリッジ キャンサー ダイアグノスティクス リミテッド filed Critical ケンブリッジ キャンサー ダイアグノスティクス リミテッド
Publication of JP2011501809A publication Critical patent/JP2011501809A/ja
Application granted granted Critical
Publication of JP5559056B2 publication Critical patent/JP5559056B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010529444A 2007-10-15 2008-10-15 ガンの診断、予測、および予後試験 Expired - Fee Related JP5559056B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0720113.0 2007-10-15
GBGB0720113.0A GB0720113D0 (en) 2007-10-15 2007-10-15 Diagnostic, prognostic and predictive testing for cancer
PCT/GB2008/003501 WO2009050461A1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014018906A Division JP5837630B2 (ja) 2007-10-15 2014-02-03 ガンの診断、予測、および予後試験

Publications (2)

Publication Number Publication Date
JP2011501809A JP2011501809A (ja) 2011-01-13
JP5559056B2 true JP5559056B2 (ja) 2014-07-23

Family

ID=38813827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010529444A Expired - Fee Related JP5559056B2 (ja) 2007-10-15 2008-10-15 ガンの診断、予測、および予後試験
JP2014018906A Expired - Fee Related JP5837630B2 (ja) 2007-10-15 2014-02-03 ガンの診断、予測、および予後試験

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014018906A Expired - Fee Related JP5837630B2 (ja) 2007-10-15 2014-02-03 ガンの診断、予測、および予後試験

Country Status (11)

Country Link
US (3) US8512716B2 (https=)
EP (1) EP2208070B1 (https=)
JP (2) JP5559056B2 (https=)
CN (1) CN101896819A (https=)
AU (1) AU2008313459B2 (https=)
CA (1) CA2702653A1 (https=)
DK (1) DK2208070T3 (https=)
ES (1) ES2395890T3 (https=)
GB (1) GB0720113D0 (https=)
PT (1) PT2208070E (https=)
WO (1) WO2009050461A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
WO2012012693A2 (en) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
AU2013388864B2 (en) * 2013-05-09 2017-06-08 The Procter & Gamble Company Method and system for assessing health condition
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
US9857354B2 (en) 2014-06-01 2018-01-02 Novazoi Theranostics, Inc. Compositions and methods for prognosis and treatment of neoplasm
WO2016131875A1 (en) * 2015-02-17 2016-08-25 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of bladder cancer
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344867B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN108344868B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN109988708B (zh) * 2019-02-01 2022-12-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN110846413B (zh) * 2019-11-23 2023-05-26 中南大学湘雅三医院 Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
WO2023150578A2 (en) * 2022-02-01 2023-08-10 4D Path Inc. Systems and methods for image-based disease characterization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2563168A1 (en) * 2004-04-14 2005-11-17 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
EP1805676A1 (en) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
ATE464395T1 (de) * 2005-02-18 2010-04-15 Astrazeneca Ab Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
ATE456053T1 (de) * 2005-12-30 2010-02-15 Ventana Med Syst Inc Na+, k+-atpase-expression bei zervixdysplasie und krebs

Also Published As

Publication number Publication date
US8512716B2 (en) 2013-08-20
CN101896819A (zh) 2010-11-24
US20140154680A1 (en) 2014-06-05
PT2208070E (pt) 2013-01-08
CA2702653A1 (en) 2009-04-23
EP2208070A1 (en) 2010-07-21
GB0720113D0 (en) 2007-11-28
DK2208070T3 (da) 2012-12-17
US20180223366A1 (en) 2018-08-09
JP2014095726A (ja) 2014-05-22
AU2008313459A1 (en) 2009-04-23
ES2395890T3 (es) 2013-02-15
JP5837630B2 (ja) 2015-12-24
US20100285474A1 (en) 2010-11-11
EP2208070B1 (en) 2012-10-03
WO2009050461A1 (en) 2009-04-23
AU2008313459B2 (en) 2013-01-24
JP2011501809A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
JP5837630B2 (ja) ガンの診断、予測、および予後試験
EP2606349A1 (en) Cancer diagnostic and cancer therapeutic
US20100081666A1 (en) Src activation for determining cancer prognosis and as a target for cancer therapy
US20240084400A1 (en) Methods for prognosing, diagnosing, and treating colorectal cancer
Li et al. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
US20120245051A1 (en) Objective, quantitative method to predict histological subtype in non-small cell lung cancer
Yang et al. HMGA1 promotes hepatic metastasis of colorectal cancer by inducing expression of glucose transporter 3 (GLUT3)
US20140186837A1 (en) Methods For Diagnosing Cancer
Chen et al. The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma
Li et al. Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma
Wang et al. CCT6A is associated with CDC20, Enneking stage and prognosis in osteosarcoma, and its knockdown suppresses osteosarcoma cell viability and invasion
JP2017508147A (ja) ステージｉｉの結腸直腸がんにおける予測マーカーとしてのｇアルファ相互作用小胞結合タンパク質（ｇｉｖ）
Li et al. RETRACTED ARTICLE: Octamer transcription factor 1 mediates epithelial-mesenchymal transition in colorectal cancer
Mamat@ Yusof et al. Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer
GB2519830A (en) Methods for monitoring treatment response and relapse in ovarian cancer
Hunt et al. Extensive intratumor proteogenomic heterogeneity revealed by multiregion sampling in high-grade serous Ovarian tumor specimens
EP2574929A1 (en) Marker in diagnosing prostate cancer (PC)
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
JP2017529074A (ja) 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
US11360094B2 (en) Method for measuring MRE11 in tissues to predict cystectomy or bladder sparing surgery plus chemoradiation therapy
Rabien et al. Cancer Treated by Adjuvant Chemotherapy
Makise et al. HMGA2 expression in CIC‐rearranged sarcoma and other small round/epithelioid cell tumours
Abd-Rabh et al. Significance of Ubiquitin-Conjugating Enzyme (UBE2C) and P53 Expression in Molecular Subtypes of Breast Carcinoma; An Immunohistochemical Study
Scerri Herceptin® resistance in breast cancer: a pathwaybased approach
Villman Chemosensitivity in Breast Cancer

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140605

R150 Certificate of patent or registration of utility model

Ref document number: 5559056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees